The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
Your search for bevacizumab returned 2 results
There was no improvement in overall survival with bevacizumab.
- Loading...
